Risk for T2DM Increased With Use of 5α-Reductase Inhibitors
Increased risk seen among men using dutasteride, finasteride for benign prostatic hyperplasia
Diabetes
Early T2DM Diagnosis Linked to Increased Cardiovascular Risk
Highest excess risk for mortality, CV mortality, heart failure, CHD seen for T2DM patients diagnosed before 40
FDA Warns Against Use of Preowned or Unauthorized Test Strips
Unauthorized, preowned test strips could cause infection, inaccuracy
11 Million Deaths Attributable to Poor Diet in 2017
Leading dietary risk factors for deaths, DALYs include high sodium intake, low intake of whole grains
Invokana sNDA Seeking Treatment of Chronic Kidney Disease in T2D Patients
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.
HbA1c Test Significantly Underestimates Diabetes Prevalence
Investigators examined glucose tolerance defined by hemoglobin A1c to the oral glucose tolerance test.
Statins Tied to Insulin Resistance, Higher Serum Fasting Insulin
Ever use of statins associated with 38 percent increased risk for incident type 2 diabetes
Radiographic Knee OA Tied to Death Risk From Diabetes, Kidney Diseases
Risk higher for cardiovascular disease, diabetes, renal mortality; lower risk for cancer mortality
Small Increase in HbA1c Seen With Switch to Human Insulin in T2DM
No increase in serious hypoglycemia, hyperglycemia after switch from analogue to human insulin
Kidney Failure Risk Minimal Following Diabetes Diagnosis
In a Finnish study, the cumulative risk for end-stage renal disease among patients with newly diagnosed with type 2 diabetes was less than 1% at 20 years.
Next post in Diabetic Nephropathy
